Rodman & Renshaw Maintains St. Jude Medical Market Perform

Rodman & Renshaw maintained its St. Jude Medical

Market Perform rating after St. Jude Medical's earnings announcement in a research report published today. In the report, Rodman & Renshaw states, "Expectations for STJ's performance in CRM remains high. Assuming MDT report numbers close to what we are expecting, then STJ's growth rates have slowed and market share has been lost. There is considerable hope that the Unify Quadra quadripolar line of CRT-D's will provide the next leg up for share gains. The company is still waiting for regulatory approval on the same. Market fundamentals combined with aggressive bundling strategies, and hospital demands on concessions are key factors that we believe are an overhang for this segment." Shares of St. Jude Medical closed today at $40.03, up 2.77% from Thursday's market close.